The concentrated selling by multiple C-suite executives, particularly the Chief Legal and Commercial Officers, signals potential lack of confidence in near-term prospects. Traders should monitor for upcoming earnings or regulatory decisions, especially around the company's lead drug candidates.
Price Chart
Executive Summary
Four executives at Travere Therapeutics sold $2.15M in shares over two days, including significant sales by the Chief Legal Officer and Commercial Officer. The CEO and CFO also sold smaller amounts, with all transactions occurring at market prices.
Key Financial Metrics
Key Facts
- Chief Legal Officer Elizabeth Reed sold $1.54M in shares (37,500 shares at $41.07), the largest individual sale in the cluster.
- Chief Commercial Officer Peter Heerma and Chief Medical Officer Jula Inrig each sold approximately $303K in shares.
- CFO Christopher Cline sold 9 shares for $370 on 2026-04-14 and an additional 1,014 shares for $43,207 on 2026-04-15.
- Total open-market sales by executives and insiders in the 7-day window amount to $3.0M, representing ~0.08% of the $3.8B market cap.
- Multiple non-cash derivative exercises occurred, including grants and tax-related transactions, which do not reflect open-market sentiment.
Financial Impact
$3.0M in insider sales over 7 days, with $2.15M concentrated in a 2-day window among C-suite executives
Risk Factors
- Insider selling may indicate anticipation of negative news or lack of confidence in current valuation.
- Potential for downward pressure on share price if retail investors interpret this as a bearish signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-TVTX-1776369945426 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 9, 2026 12w ago | 8-K | $56.59 $61.32 | ▲ +8.36% | ▲ +5.93% | $56.93 (+0.60%) |
Jun 16, 2026 15w ago | Insider Cluster | $54.14 $55.28 | ▲ +2.11% | ▲ +0.79% | $56.93 (+5.15%) |
Jun 16, 2026 15w ago | 8-K | $54.14 $55.28 | ▲ +2.11% | ▲ +0.79% | $56.93 (+5.15%) |
Jun 12, 2026 16w ago | 144 | $52.04 $56.59 | ▲ +8.74% | ▲ +6.96% | $56.93 (+9.40%) |
Jun 2, 2026 17w ago | 8-K | $42.96 $56.34 | ▲ +31.15% | ▲ +32.71% | $56.93 (+32.52%) |
May 15, 2026 20w ago | 144 | $42.59 $53.80 | ▲ +26.32% | ▲ +24.20% | $56.93 (+33.67%) |
May 5, 2026 21w ago | 144 | $44.76 $45.20 | ▲ +0.98% | ▼ −1.80% | $56.93 (+27.19%) |
May 4, 2026 21w ago | 144 | $44.80 $42.96 | ▼ −4.11% | ▼ −9.06% | $56.93 (+27.08%) |
May 1, 2026 22w ago | Insider Cluster | $44.12 $45.04 | ▼ −2.09% | ▲ +3.20% | $56.93 (−29.03%) |
Apr 15, 2026 24w ago | 144 | $40.95 $42.84 | ▲ +4.62% | ▼ −1.43% | $56.93 (+39.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access